Challenges include increased awareness of the need for early screening, evaluation and initiation of tx to avoid rapid progression of pulmonary disease with irreversible loss of pulmonary function and to work as a multidisciplinary team of PCP, Rheumatologist, Pulmonologist and Cardiologist to provide comprehensive care, and hopefully development of new drugs in addition to the anti-fibrotics and biologics such as Actemra and Rituxan.
RHEUMATOLOGY NATION